Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Choi, Briana
Alkhatib, Nimer S.
Pae, Elizabeth
Babiker, Hani M.
Garland, Linda L.
Henglefelt, Alyssa
McBride, Ali
Abraham, Ivo
机构：
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Univ Arizona, Tucson, AZ USA
[3] Univ Arizona, Ctr Canc, Tucson, AZ USA
[4] Bannar Univ Med Hosp, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20714
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatininb in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC) as second-line treatment.
    Alkhatib, Nimer S.
    Choi, Briana
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC) refractory to alectinib
    Ou, S-H. I.
    Nishio, M.
    Yoshida, T.
    Ahn, M-J.
    Mok, T. S. K.
    Kudou, K.
    Asato, T.
    Yang, H.
    Tong, X.
    Zhang, P.
    Yamamoto, N.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1015
  • [4] Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS).
    Alkhatib, Nimer S.
    Choi, Briana
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] COST-EFFECTIVE STUDY OF ALECTINIB IN TREATING CRIZOTINIB-FAILED ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN TAIWAN
    Liao, C.
    Wang, C.
    Chan, K. A.
    Hsiao, F.
    VALUE IN HEALTH, 2018, 21 : S34 - S34
  • [6] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [7] BUDGET IMPACT OF ALECTINIB IN THE TREATMENT OF NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
    Kourkoulas, N.
    Kyriopoulos, D.
    Athanasakis, K.
    VALUE IN HEALTH, 2017, 20 (09) : A424 - A424
  • [8] Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
    Reckamp, Karen
    Lin, Huamao M.
    Huang, Joice
    Proskorovsky, Irina
    Reichmann, William
    Krotneva, Stanimira
    Kerstein, David
    Huang, Hui
    Lee, Joseph
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 569 - 576
  • [9] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [10] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
12345